Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveFactors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantationImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Skin concentrations and pharmacokinetics of posaconazole after oral administration.Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapyClinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Relevance of timing for determination of posaconazole plasma concentrationsSuperior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.New generation azole antifungals in clinical investigation.Pediatric antifungal agents.Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.Use of posaconazole in the treatment of invasive fungal infections.Therapeutic drug monitoring of voriconazole and posaconazole.Posaconazole: when and how? The clinician's view.The use of antifungal therapy in neonatal intensive care.Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.Dosing of antifungal agents in obese people.Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation.Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
P2860
Q27009221-F0D25907-1D38-47EF-B7CA-2CE7A2D8F306Q33559111-06EFCE65-E0EE-492D-8AFC-30C397D8660AQ33726698-C89B353D-5A9B-40DC-9EB6-FC1181E03F8DQ33764269-F25C5B76-45E8-4A33-81E2-5899F09CF7ADQ33798286-4809837C-99F7-4E1D-97D6-EB943C0281B6Q33798313-D43B5AA5-8D93-4F04-8318-D2D67790D4C5Q33826421-6E553362-1B75-4C47-B83A-60150186DEAAQ34108650-2A889794-7091-47AD-8DEE-A661BE424525Q34299092-324C0849-5949-470F-A12B-796804B1B160Q34596750-F1D8D8EB-5F07-4961-BDDF-B0F832C893C9Q34737174-D6EC7D32-9BD6-4CC7-9D03-A77550193080Q35026481-C55F59E3-E6DC-4F28-9BCF-F725AAE2B6B0Q35065721-6EB9D542-5EDF-48BB-8472-34DE5210CB50Q35859959-7C296E39-B82B-4D25-9315-40F3B6652E45Q35941414-7654F04E-F6EC-4AA4-BF37-3D7358BA5D94Q35959480-0143C545-412A-4976-B26C-F47D88048009Q36018743-307E5165-57B6-4B56-B189-38A7BA01ED78Q36171677-957783A1-0F4E-418E-9168-8466D20B822CQ36276966-0499B151-2791-4E9A-80A6-AF6AF42AE093Q36364013-60474813-2776-4F19-BC5F-71FC06493B51Q36396203-9A28C151-E60A-48F7-B9E1-936A1E93E368Q37115829-AFA01EF8-F594-454C-AECC-0DF9B6687637Q37404840-892B1400-9FBA-40E6-B9CC-764E191A3189Q37450660-ECDA7E62-B60D-434A-83CB-29DD7837B975Q37579222-9FF72EA2-7155-4BA7-A51B-457AA12C7C13Q37594515-BEA92915-D164-45BA-8D78-8699A3DFA2C0Q37761047-24629A96-D94C-4ADC-8940-E3B271FD5B20Q37810083-A38426AC-D00E-409F-A1FE-24B90D6B69B9Q37833074-123CD810-E5DF-4492-8277-4362EF2BD0DEQ37901534-F8D26D95-6D7A-4AD3-83A4-52DE64476DB4Q37985070-51487AC3-D0AB-4FDB-83AC-23954669C30AQ38122347-78A0BE9F-5A26-4C0C-9D11-913E22ED249FQ38193337-3023E02F-4408-4738-8115-37E951689DE8Q38284468-40B7B78C-B89C-471B-BB87-1AAE8C19FC1CQ38321383-91534CC9-9C18-46A6-A9C0-CEC4DDBBED6EQ38341595-199F55E7-ABC1-4F83-B25D-40A264A8D822Q38660761-30B920DC-A5CA-42B8-A327-B81A00D9F8F0Q40140538-912CBD7E-1071-4E38-AA2F-B36D8217C05DQ40298087-1181DF31-FA8C-4049-A363-87592B3A3ED6Q40309090-C6B758D6-E782-44C4-BA92-ED320F741E43
P2860
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@en
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@nl
type
label
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@en
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@nl
prefLabel
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@en
Pharmacokinetics of oral posac ...... a or myelodysplastic syndrome.
@nl
P2093
P2860
P921
P356
P1433
P1476
Pharmacokinetics of oral posac ...... ia or myelodysplastic syndrome
@en
P2093
David Angulo
Fengjuan Xuan
Gopal Krishna
Malaz AbuTarif
Monika Martinho
P2860
P304
P356
10.1592/PHCO.28.10.1223
P407
P577
2008-10-01T00:00:00Z